JPWO2022228495A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022228495A5
JPWO2022228495A5 JP2023566660A JP2023566660A JPWO2022228495A5 JP WO2022228495 A5 JPWO2022228495 A5 JP WO2022228495A5 JP 2023566660 A JP2023566660 A JP 2023566660A JP 2023566660 A JP2023566660 A JP 2023566660A JP WO2022228495 A5 JPWO2022228495 A5 JP WO2022228495A5
Authority
JP
Japan
Prior art keywords
atoms
optionally substituted
linear
cycloalkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522389A5 (https=
JP2024522389A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/089726 external-priority patent/WO2022228495A1/zh
Publication of JP2024522389A publication Critical patent/JP2024522389A/ja
Publication of JPWO2022228495A5 publication Critical patent/JPWO2022228495A5/ja
Publication of JP2024522389A5 publication Critical patent/JP2024522389A5/ja
Pending legal-status Critical Current

Links

JP2023566660A 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用 Pending JP2024522389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110475315 2021-04-29
CN202110475315.1 2021-04-29
PCT/CN2022/089726 WO2022228495A1 (zh) 2021-04-29 2022-04-28 抗体偶联药物的制备方法及应用

Publications (3)

Publication Number Publication Date
JP2024522389A JP2024522389A (ja) 2024-06-19
JPWO2022228495A5 true JPWO2022228495A5 (https=) 2025-04-16
JP2024522389A5 JP2024522389A5 (https=) 2025-04-16

Family

ID=83846703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023566660A Pending JP2024522389A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566547A Pending JP2024522312A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566659A Pending JP2024522388A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023566547A Pending JP2024522312A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566659A Pending JP2024522388A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Country Status (10)

Country Link
US (3) US20240238440A1 (https=)
EP (3) EP4331612A1 (https=)
JP (3) JP2024522389A (https=)
KR (2) KR20240006029A (https=)
CN (3) CN117241834A (https=)
AU (1) AU2022263700A1 (https=)
CA (3) CA3173902A1 (https=)
IL (1) IL308025A (https=)
TW (3) TW202308700A (https=)
WO (3) WO2022228494A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117241834A (zh) * 2021-04-29 2023-12-15 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用
IL319963A (en) 2022-10-19 2025-05-01 Multitude Therapeutics Inc Antibodies, antibody-drug conjugates, compositions and uses thereof
CN120417935A (zh) * 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
CN120882431A (zh) * 2023-01-11 2025-10-31 金麦安博股份有限公司 接头、药物接头及其缀合物和使用它们的方法
CN118684724A (zh) * 2023-03-22 2024-09-24 映恩生物制药(苏州)有限公司 连接子及其在配体药物偶联物中的应用
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
WO2024212922A1 (zh) * 2023-04-11 2024-10-17 映恩生物制药(苏州)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
CN119300868B (zh) * 2023-05-11 2026-03-13 映恩生物科技(上海)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
EP4713020A2 (en) * 2023-05-19 2026-03-25 Solve Therapeutics, Inc. Drug-linkers and drug conjugates
CN121772941A (zh) * 2023-06-07 2026-03-31 维申医药(南通)有限公司 一种抗体药物偶联物,及其药物组合物、制备和用途
WO2025005240A1 (ja) * 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体-薬物コンジュゲートの製造方法
AU2024288808A1 (en) 2023-07-07 2026-01-22 Shanghai Escugen Biotechnology Co., Ltd. Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof
IL326233A (en) * 2023-08-04 2026-03-01 Shanghai Huao Co Ltd Multidrug Linker and Antibody-Drug Conjugation
CN120641100A (zh) * 2023-09-22 2025-09-12 台湾浩鼎生技股份有限公司 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用
TW202525860A (zh) * 2023-10-23 2025-07-01 大陸商上海齊魯製藥研究中心有限公司 喜樹鹼類藥物耦合物及其製備方法和應用
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
WO2025149019A1 (en) * 2024-01-12 2025-07-17 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
WO2025222052A2 (en) * 2024-04-18 2025-10-23 Solve Therapeutics, Inc. Conjugates and uses thereof
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2025261478A1 (en) * 2024-06-21 2025-12-26 Biotheus Inc. Antibody drug conjugates and applications thereof
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026037394A1 (zh) * 2024-08-16 2026-02-19 石药集团巨石生物制药有限公司 一种抗体药物偶联物及其用途
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof
WO2026067624A1 (zh) * 2024-09-27 2026-04-02 上海森辉医药有限公司 一种包含亲水基团的配体-药物偶联物及其在医药上的应用
CN119143876B (zh) * 2024-10-09 2025-09-16 武汉海沙百得生物技术有限公司 一种抗cd27l的全人源抗体或抗体片段及其应用
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof
CN120484249B (zh) * 2025-04-29 2026-03-10 中山大学 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
DE60235287D1 (de) * 2001-11-14 2010-03-25 Univ Rutgers Löslich gemachte topoisomerase-gifte
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
RU2015129800A (ru) * 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
WO2014177042A1 (zh) * 2013-04-28 2014-11-06 Qin Gang 一种新型的连接子及其制备方法和用途
LT3424955T (lt) * 2013-12-25 2025-06-25 Daiichi Sankyo Company, Limited Anti-trop2 antikūno ir vaisto konjugato gamybos būdas
AU2015252518B2 (en) * 2014-04-29 2019-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method therefor, and use thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
US10675357B2 (en) 2015-09-09 2020-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to nectin-4 and uses thereof
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
TW202532102A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド-薬物-複合体
KR20220010527A (ko) * 2019-05-20 2022-01-25 노파르티스 아게 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
JP7167163B2 (ja) 2019-05-20 2022-11-08 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 抗体-薬物コンジュゲートの中間体のワンポット合成法による製造プロセス
CN117241834A (zh) * 2021-04-29 2023-12-15 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用

Similar Documents

Publication Publication Date Title
JPWO2022228495A5 (https=)
JPWO2022228494A5 (https=)
JPWO2022228493A5 (https=)
Zhao et al. Synthesis and evaluation of hydrophilic linkers for antibody–maytansinoid conjugates
Elgersma et al. Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody–drug conjugate SYD985
JP6445519B2 (ja) ピロロベンゾジアゼピン及びそのコンジュゲート
JP2012516896A5 (https=)
JP2024522388A (ja) 抗体薬物複合体の調製方法および使用
HRP20250345T1 (hr) Konjugati antitijelo - lijek derivata cikličnih dinukleotida
HRP20151374T1 (hr) Pirolobenzodiazepini i njihovi konjugati
RU2017131902A (ru) Цитотоксические производные бензодиазепина
RU2017123942A (ru) Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
JP2018503639A5 (https=)
RU2011136686A (ru) Новые производные бензодиазепина
JP2012522512A5 (https=)
JP2014534199A5 (https=)
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP2021525730A5 (https=)
WO2024041542A1 (en) A method for programmatically managing antibody disulfide bonds site-specific modification
JPWO2020106780A5 (https=)
JP2007519681A (ja) 新規なエフェクター複合体、それらを製造する方法およびそれらの薬学上の使用
RU2023130984A (ru) Способ получения и применение конъюгата антитело-лекарственное средство
RU2023112017A (ru) Дейтерированное производное камптотецина и включающий его конъюгат антитело-лекарственное средство
RU2025110275A (ru) Лекарственное средство на основе ауристатина с высокостабильным гидрофильным линкерным элементом и его конъюгат
JP2023514520A (ja) ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体-薬物複合体